Catherine Coleman

Catherine Coleman's AcademicInfluence.com Rankings

Catherine Coleman

Computer Science

#11333

World Rank

#11998

Historical Rank

Informatics

#72

World Rank

#76

Historical Rank

computer-science Degrees

Catherine Coleman

Philosophy

#11236

World Rank

#15445

Historical Rank

Logic

#8045

World Rank

#10009

Historical Rank

philosophy Degrees

Download Badge

Computer Science
Philosophy

Catherine Coleman's Degrees

Doctorate Medicine Stanford University

Why Is Catherine Coleman Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Catherine Coleman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. (1999) (381)
Analysis of prostate and seminal vesicle motion: implications for treatment planning. (1996) (273)
Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity. (1988) (258)
Improved methodology for analyzing local and distant recurrence. (1990) (221)
Real-time magnetic resonance image-guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer. (1998) (207)
Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. (1988) (166)
Radioimmunotherapy with alpha-particle-emitting immunoconjugates. (1988) (161)
Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. (1988) (155)
Stereotactic radiosurgery for intracranial arteriovenous malformations using a standard linear accelerator. (1989) (155)
Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. (1990) (137)
Chemical modifiers of cancer treatment. (1988) (129)
Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. (1986) (129)
Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). (1986) (122)
Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. (1997) (110)
Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy (1994) (104)
Workshop on partial breast irradiation: state of the art and the science, Bethesda, MD, December 8-10, 2002. (2004) (96)
Analysis of prostate and seminal vesicle motion (1993) (92)
Modulation of radiation-induced apoptosis and G2/M block in murine T-lymphoma cells. (1995) (88)
Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508. (1984) (86)
Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. (1996) (79)
5 year biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer (1998) (78)
Clinical radiosensitization: why it does and does not work. (1999) (71)
Radiation and chemotherapy sensitizers and protectors. (1990) (65)
Minimal long-term cardiopulmonary dysfunction following treatment for Hodgkin's disease. (1987) (64)
Secondary neoplasms in patients treated for cancer: etiology and perspective. (1982) (63)
Hypoxic cell radiosensitizers: expectations and progress in drug development. (1985) (61)
Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile. (1987) (61)
Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule. (1986) (60)
The use of probenecid as a chemoprotector against cisplatin nephrotoxicity (1991) (55)
A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. (2003) (55)
Modifiers of radiation-induced apoptosis. (1993) (52)
Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. (1994) (50)
Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma. (1992) (49)
Alpha particle radio-immunotherapy: animal models and clinical prospects. (1989) (49)
Biologic basis for radiation oncology. (1996) (48)
Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. (1984) (46)
Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward? (1984) (42)
Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03. (1990) (41)
Secondary malignancy after treatment of Hodgkin's disease: an evolving picture. (1986) (39)
Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. (1999) (38)
Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin. (1997) (37)
Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo. (1990) (36)
Initial pharmacology and toxicology of intravenous desmethylmisonidazole. (1982) (30)
Sensitizers and protectors of radiation and chemotherapy. (2001) (30)
Signal transduction inhibitors as modifiers of radiation therapy in human prostate carcinoma xenografts (1996) (29)
Splenic injury caused by therapeutic irradiation (1981) (28)
Interaction of tomudex with radiation in vitro and in vivo. (1998) (24)
Radiation-induced apoptosis in F9 teratocarcinoma cells. (1994) (24)
Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV. (1997) (22)
Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. (1998) (22)
The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer. (1992) (21)
Rate of relapse following treatment for localized prostate cancer: a critical analysis of retrospective reports. (1994) (21)
Effect of cell cycle stage, dose rate and repair of sublethal damage on radiation-induced apoptosis in F9 teratocarcinoma cells. (1995) (21)
Protection against SR 4233 (Tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron. (1994) (20)
Initial results of a phase I trial of continuous infusion SR 2508 (etanidazole): a radiation therapy oncology group study. (1989) (20)
Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. (1991) (19)
Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20). (1996) (19)
Enhancement of the clinical activity of melphalan by the hypoxic cell sensitizer misonidazole. (1988) (18)
Training the radiation oncologist for the twenty-first century. (1996) (18)
Beneficial liaisons: radiobiology meets cellular and molecular biology (1993) (18)
Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole. (1983) (17)
Novel concepts in modification of radiation sensitivity. (1994) (17)
Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial. (1997) (16)
Effects of nitroimidazoles on neuronal cells in vitro. (1989) (16)
Modulating the Radiation Response (1996) (15)
SR-4233 (Tirapazamine) acts as an uncoupler of oxidative phosphorylation in human MCF-7 breast carcinoma cells. (1994) (15)
RTOG #89-06: a phase I study to evaluate intraoperative radiation therapy and the hypoxic cell sensitizer etanidazole in locally advanced malignancies. (1994) (15)
Bioreductive metabolism of SR-4233 (WIN 59075) by whole cell suspensions under aerobic and hypoxic conditions: role of the pentose cycle and implications for the mechanism of cytotoxicity observed in air. (1994) (15)
Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a Radiation Therapy Oncology Group study. (1992) (15)
Beneficial liaisons: radiobiology meets cellular and molecular biology. (1993) (14)
A phase I study of etanidazole and radiotherapy in malignant glioma. (1994) (13)
Molecular biology in radiation oncology. Radiation oncology perspective of BRCA1 and BRCA2. (1999) (13)
Distribution of etanidzole into human brain tumors: Implications for treating high grade gliomas (1992) (12)
New directions in brachytherapy. (2002) (11)
Prostate cancer. Technology versus biology (1993) (10)
Chemical sensitizers and protectors. (1998) (10)
Of what use is molecular biology to the practicing radiation oncologist? (1998) (10)
Current scientific issues related to clinical radiation oncology. (1998) (10)
Results of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (1984) (10)
Pharmacodynamics of prolonged treatment with L,S-buthionine sulfoximine. (1994) (10)
Modification of the aerobic cytotoxicity of etanidazole. (1994) (10)
Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer. (1994) (9)
Estimating the risk of second primary tumors following cancer treatment. (1989) (9)
Elevation of mouse kidney thiol content following administration of glutathione. (1992) (9)
The development of an oral prodrug, SR-2545, of the 2-nitroimidazole radiosensitizer SR-2508. (1982) (9)
Phase III study of ibuprofen versus placebo for radiation-induced genitourinary side effects. (2002) (9)
The challenge for conformal therapy for prostate cancer. (1993) (9)
Role of additional radiotherapy in advanced stages of Hodgkin's disease. (1992) (8)
Chemoradiation and adjuvant chemotherapy for glioblastoma: why does so much therapy yield so little improvement in survival? (1995) (8)
Lisofylline as a modifier of radiation therapy. (1996) (8)
Tumor oxygenation after hyperthermia in the rat 13762 mammary carcinoma and the DU-145 human prostate carcinoma. (1997) (8)
The effect of vitamin B6 on the neurotoxicity and pharmacology of desmethylmisonidazole and misonidazole: clinical and laboratory studies. (1984) (7)
Combined Modality Therapy Using Cytotoxic Agents and Radiation Therapy (1988) (7)
Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome. (1994) (6)
Effect of OH scavenging on the yield of radiation-induced DNA double-strand breaks in isolated nuclei. (1988) (6)
COMMENTARY Workshop on Partial Breast Irradiation: State of the Art and the Science, Bethesda, MD, (2004) (6)
The current status of drug development of hypoxic cell radiosensitizers and their potential role in gynecologic oncology. (1984) (5)
Inflammatory breast issue. (2003) (5)
Conference summary: the ninth international conference on the Chemical Modifiers of Cancer Treatment. (1996) (5)
Phase I pharmacokinetic study of the hypoxic cell sensitizer etanidazole with carboplatin and cyclophosphamide in the treatment of advanced ovarian cancer. (1994) (4)
Metabolic effects of antibodies on platelets. (1973) (4)
Pilot study of local hyperthermia, radiation therapy, etanidazole, and cisplatin for advanced superficial tumours. (1995) (4)
Final report: Phase I trial of desmethylmisonidazole (DMM) - an hypoxic cell sensitizer (1982) (4)
Logistics in designing clinical trials for etanidazole (SR 2508): an RTOG experience. (1992) (4)
Advances in cellular and molecular radiation oncology. (1996) (4)
Alternative and future strategies in the treatment of malignant gliomas (1991) (3)
Analyzing local and distant recurrence (Reply) (1990) (3)
The hall-mark of modern radiation oncology. (1994) (3)
Reversal of drug-resistance by exposure of mcf-7 or mcf-7 cddp human breast-carcinoma cells to sr-4233 or etanidazole under hypoxic conditions. (1993) (3)
We're from the Government and We're Here to Help You (1994) (3)
Research in medical physics. (2001) (3)
Neuropathy of desmethylmisonidazole (DMM): Clinical and pathological description (1982) (3)
Distribution of etanidazole into human brain tumors: implications for treating high grade gliomas. (1992) (3)
Can irradiation of lewis lung carcinoma primary tumor cause the growth of lung metastases (1998) (3)
CT of irradiated solid tumor metastases to the brain (1982) (3)
Mentors, mensches, and models. (2009) (3)
Lymphoblastic lymphoma. (1990) (3)
"Reports of my death [may be] greatly exaggerated" (adapted from Mark Twain)--in response to Dr. J. M. Brown, IJROBP 32:883-885; 1995. (1995) (3)
Keynote address: Biochemical modification of therapeutic response (1992) (2)
CLINICAL TRIALS OF ETANIDAZOLE (SR 2508): RTOG AND JOINT CENTER FOR RADIATION THERAPY TRIALS (1992) (2)
2023 Survival results of a phase I study of etanidazole and radiotherapy in patients with malignant glioma (1996) (2)
Carcinoma of the prostate: praising Stanford's accomplishments. (1994) (2)
Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study. (1994) (2)
Modification of radiotherapy by radiosensitizers and cancer chemotherapy agents. I. Radiosensitizers. (1989) (2)
Transitioning to Environmentally Sustainable, Climate-Smart Radiation Oncology Care. (2022) (2)
Re: The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. (1994) (2)
A phase I pilot study to evaluate intraoperative radiation therapy (IORT) and the hypoxic cell sensitizer etanidazole (ETA) in patients with locally advanced malignancies (RTOG protocol 89-06) (1992) (2)
Hypoxic cell sensitizers: Theoretical approaches and clinical strategies (1990) (1)
Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH) (2020) (1)
Phase I trial of desmethylmisonioazole — A new hypoxic cell sensitizer (1981) (1)
Pharmacology and toxicology of desmethylmisonidazole (DMM) - An hypoxic cell sensitizer (1982) (1)
S17 05 TA – CLINICAL TRIALS WITH ETANIDAZOLE (SR 2508) (1991) (1)
1002 Equivalent 5 year bNED in select prostate cancer patients managed with surgery or radiation therapy despit exclusion of the seminal vesicles from the clinical target volume (1997) (1)
Investing in our future: listening to those who will take us where we need to go. (2001) (1)
Hypoxic Cell Sensitizers (1991) (1)
Current role of nitroimidazole sensitizers and sulfhydryl protectors in clinical oncology (1982) (0)
Chemical modifiers of radiation and chemotherapy: tumor sensitization and normal tissue protection (1984) (0)
Progress in systemic radiotherapy. Authors' reply (2005) (0)
201C Molecular biology — Part II: Beneficial liaisons: Radiobiology meets cellular and molecular biology (1996) (0)
62 ASTRO fellowship project: Heat shock proteins and apoptosis in prostate adenocarcinoma (1996) (0)
THERMOCHEMORADIOTHERAPY IN VIVO (1991) (0)
Are radiation oncologists serious about systemic radiation therapy and if not, should we be? (2004) (0)
Biochemical modification of therapeutic response. (1992) (0)
NAPRT1 and p53 Status in Cancer and Normal Cells Modulate Induction of ROS Induced by GMX1777/1778: Implication for Synthetic Lethality in Tumors Defective in NAPRT1 and p53 (2010) (0)
CHAPTER 12 CYTOGENETIC BIODOSIMETRY (2012) (0)
ASTRO refresher course descriptionHypoxic cell sensitizers: Theoretical approaches and clinical strategie (1990) (0)
18 Novel radiation modifiers (1995) (0)
The Harvard Joint Center for Radiation Therapy, 1968-1999: a unique concept and its relationship to the prevailing times in academic medicine. (2000) (0)
183Of what use is molecular and cellular biology to the practicing radiation oncologist (1996) (0)
In response to Dr. Order (2005) (0)
Urologic oncology: extraordinary opportunities for discovery (2001) (0)
Effect of BSO and etanidazole on neurofilament degradation in neonatal rat spinal cord cultures. (1996) (0)
Inhibition of c/s-Diamminedichloroplatinum Secretion by the Human Kidney with Probenecid1 (2006) (0)
Career Options in Radiation Oncology (2021) (0)
Sensitization of Chinese hamster ovary cells to melphalan by etanidazole under intermittent hypoxia. (1992) (0)
39 Normal tissue countermeasures (2006) (0)
In response to Drs. Schulz and Kagan (2002) (0)
The effect of postoperative (POSTOP) and primary radiation therapy (RT) on delivered dose of adjuvant cytoxan, methotrexate, 5-FU (CMF) chemotherapy (CT) in breast cancer (1982) (0)
Protection against SR 4233 aerobic cytotoxicity by the metal chelators desferrioxamine and tiron (1993) (0)
Therapeutic implications of prolonged treatment with L,S,-Buthione sulfoximine (1992) (0)
7 Hypoxic Cell Sensitizers (1991) (0)
Pretreatment N omogram f or P rostate-Specifi c A ntigen Recurrence A fter R adical P rostatectomy o r E xternal-Beam Radiation T herapy f or C linically L ocalized P rostate C ancer (1999) (0)
Modulation of Radiation-Induced Apoptosis (2021) (0)

This paper list is powered by the following services:

Catherine Coleman's Academic­Influence.com Rankings

Catherine Coleman's Degrees

Why Is Catherine Coleman Influential?

Catherine Coleman's Published Works

Published Works

Catherine Coleman's AcademicInfluence.com Rankings